Navigation Links
MicroRNAs may be key to HIV's ability to hide, evade drugs, Jefferson scientists find
Date:9/30/2007

(PHILADELPHIA) Tiny pieces of genetic material called microRNA (miRNA), better known for its roles in cancer, could be a key to unlocking the secrets of how HIV, the AIDS virus, evades detection, hiding in the immune system. Researchers at Jefferson Medical College in Philadelphia have shown that when an individual infected with HIV receives a powerful cocktail of antiviral agents called HAART (highly active antiretroviral therapy), the virus calls on miRNAs to help it remain quiet and practically undetectable, temporarily shutting down its ability to replicate and infect.

The work, which appears September 30, 2007 in an early online edition of the journal Nature Medicine, may also have implications for new treatment strategies against the virus. According to Hui Zhang, M.D., Ph.D., associate professor of Medicine in the Division of Infectious Diseases at Jefferson Medical College of Thomas Jefferson University, who led the work, if researchers can learn to manipulate miRNAs inhibitory effect on HIV, they might be able to devise strategies to bring the virus out of hiding, or latency, making it vulnerable to drugs and the bodys immune system.

While HAART can drive the number of HIV particles in the blood to practically undetectable levels, the virus is not eliminated. It hides in resting immune system CD4 T cells in the body, including the testis, brain, and other places. The drug combination has to be taken the rest of the patients life; if halted, the virus becomes active again.

HIV latency and how to eliminate the replication-competent and hidden virus are big problems, Dr. Zhang explains, noting that the molecular mechanisms that are responsible for latency are unclear.

Dr. Zhang, post-doctoral fellow Jialing Huang, Ph.D., and their colleagues may have come across one possible explanation. HIV, they have found, recruits cellular miRNA noncoding genetic material that has been shown to play a variety of roles in cancer and in biological regulation in resting T cells to control the translation of viral RNA into protein. This is the last step in the creation of HIV antigens, which make the virus visible to the immune system.

The team showed that a cluster of miRNAs bind to a certain location on the viral RNA, which in turn, blocks the creation of important proteins, and HIV replication. Resting CD4 T cells, they found, are enriched with more than the normal amount of these miRNAs compared to the activated T cells. When the researchers used antisense technology to block miRNA-caused viral inhibition, they found that the HIV again was active and able to replicate proving miRNAs critical role in maintaining latency.

While Dr. Zhang and his team continue to study how cellular miRNA contributes to latency, he notes that using miRNA inhibitors might become a kind of therapeutic approach to get the virus out of hiding, making it visible and a target for the immune system. Thats the next step, he says.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Role Of MicroRNAs In Angiogenesis Researched
2. MicroRNAs Can Be Tumor Suppressors
3. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
4. Alcoholics are prone to disability
5. Hypertension drugs could lower Disability
6. Running delays disability in the aged
7. Restricted Activity Predicts Disability
8. Adding contrast improves ultrasounds ability to detect prostate cancer
9. CoQ10 bioavailability increased by Nanotechnology
10. Amputation may depend on availability of vascular surgeons
11. The growing availability of Fake drugs in the market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that Mr. Michael ... the upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, ...
(Date:1/18/2017)... ... ... Floundering on New Year’s resolutions? Need an excuse to get back on ... U.S. Apple Association agrees and recommends starting each day with apples, a habit ... disease. , The U.S. Apple Association – which represents apple growers and producers nationwide ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... its lead compound DMT210, in a Phase 2 ... specifically developed to downregulate the proinflammatory cytokines in ... seen in acne rosacea. This ...
(Date:1/18/2017)... January 18, 2017 The report " Automated Breast Ultrasound ... Volume Scanner), By End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional ... Argentina , Germany , UK, France ... Russia , China , Japan ... Thailand , Saudi Arabia , UAE, South ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC ... has granted a Rare Pediatric Disease (RPD) designation for ... Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin ... and treatment is limited to supportive care. ... Orphan Drug Designation previously granted by the FDA in ...
Breaking Medicine Technology: